Description
Anti-TACI Antibody, ADCC Enchanced (BioBet-CB-048LX) is a glycosylation-modified anti-TACI therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TACI antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TACI
Full Name
TNF receptor superfamily member 13B
Background
TACI is a BLyS receptor and can be shed from cells' surface and circulate in soluble form (sTACI). BLyS is involved in CLL biology and its low soluble serum levels related to a shorter time to first treatment (TFT).
Alternative Names
Tumor necrosis factor receptor superfamily member 13B; Transmembrane activator and CAML interactor; CD antigen CD267; TNFRSF13B; TACI
Gene ID
23495
UniProt ID
O14836
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-CB-048LX
Description
ADCC-Enhanced Anti-Human TACI (Ianalumab) Antibody is derived from clone Ianalumab, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the TACI, and it is intended for the research of Autoimmune hepatitis.
Antibody Indication
Autoimmune hepatitis
